Search
axitinib (Inlyta)
FDA-approved Jan 27, 2012
Indications:
- treatment of advanced renal cell carcinoma after failure of one prior systemic therapy
Dosage:
- 5 mg PO BID
Tabs: 1 mg, 5 mg
Adverse effects:
1) most common
- diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot syndrome), weight decreased, vomiting, asthenia, constipation
2) severe adverse reactions
- hypertensive crisis, arterial thrombosis, venous thrombosis, hemorrhage, gastrointestinal perforation, fistula formation, reversible posterior leukoencephalopathy syndrome
Mechanism of action:
- tyrosine kinase inhibitor
- inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR & cKIT (CD117)
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
antineoplastic tyrosine kinase inhibitor
Database Correlations
PUBCHEM correlations
References
- FDA Drug approvals
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm
- Wikipedia: Axitinib
http://en.wikipedia.org/wiki/Axitinib